Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem Cells

NCT05344521 is registered in ClinicalTrials.gov with Hamilton Health Sciences Corporation as lead sponsor.

NCT NCT05344521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05344521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem Cells
Lead sponsor
Hamilton Health Sciences Corporation
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 29, 2024
Completion date
February 28, 2027
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

burns